A Maryland-based biotechnology company on Sept. 8 announced the launch of a clinical trial that will examine the efficacy and safety of a combined flu/COVID-19 vaccine.
The early-stage phase 1/2 study will examine a combination of a seasonal influenza vaccine candidate from Novavax and a COVID-19 vaccine candidate the company makes, neither of which have been authorized or approved for use in the United States.
